CircARNT2 may thus serve as an effective therapeutic target for overcoming cisplatin resistance in OC.
circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.